CC
TERN

CIBRA Capital’s Terns Pharmaceuticals TERN Stock Holding History

CIBRA Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.98M Buy
+151,440
New +$6.22M 3.85% 12

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

CIBRA Capital's TERN Position: Q1 2026 in Review

CIBRA Capital opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 151,440 shares worth $7.98M. The stake represents 3.85% of the portfolio and ranks #12 among its holdings.

317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • CIBRA Capital held 151,440 shares of Terns Pharmaceuticals worth $7.98M as of Q1 2026.
  • Terns Pharmaceuticals was a new CIBRA Capital position in Q1 2026.
  • Terns Pharmaceuticals made up 3.85% of CIBRA Capital's portfolio in Q1 2026, its #12 holding.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on CIBRA Capital's 13F filing for Q1 2026, filed 24 Apr 2026.